ACT Genomics
Provides treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $71.8m Valuation: $71.8m | Acquisition | |
| Total Funding | 000k | ||
Aflac Ventures(exited)
Sanomics(exited)
Act Genomics-Sanomics Group(exited)
Prenetics(exited)
CLSA Capital Partners(exited)
Kyoto University(exited)
CDIB Capital Group(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ACT Genomics
Edit
ACQUISITION by ACT Genomics Jul 2021